Company Analysis
Sign in

Keros Therapeutics, Inc. (KROS)

Nasdaq: KROS · Pharmaceutical Preparations · Lexington, MA · filing with the SEC since 2016
Full chart Alerts Compare
Grade7.4
◀ Past 6.2● Present 7.8▶ Future 8.1
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

15 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Keros Therapeutics, Inc.’s names, not what it holds today.

Patents granted
15
15 utility, 1976 to Dec 31, 2025
Granted in 2025
8
Against 3 in 2024 and 1 in 2023
Applications published
31
8 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals13
Biotechnology2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Keros Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
29 published
Keros Therapeutics, Inc. its own name
US, as the owner printed on each patent
15 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Dec 30, 202512,508,262Methods of using ALK2 inhibitorsPharmaceuticalsKeros Therapeutics, Inc.
Nov 4, 202512,458,693Methods of treating iron overload with a BMP inhibitorPharmaceuticalsKeros Therapeutics, Inc.
Oct 14, 202512,440,539Methods of using activin receptor type IIB variantsPharmaceuticalsKeros Therapeutics, Inc.
Sep 2, 202512,404,313GDNF fusion polypeptides and methods of use thereofBiotechnologyKeros Therapeutics, Inc.
Jul 22, 202512,364,737Activin receptor type IIA variants and methods of use thereofPharmaceuticalsKeros Therapeutics, Inc.
Jul 8, 202512,350,313Activin receptor type IIa variants and methods of use thereofPharmaceuticalsKeros Therapeutics, Inc.
Jun 17, 202512,331,124ALK2 antibodies and methods of use thereofPharmaceuticalsKeros Therapeutics, Inc.
Apr 8, 202512,269,858Activin receptor type IIB variants and methods of use thereofPharmaceuticalsKeros Therapeutics, Inc.
Aug 27, 202412,071,438Crystal forms of an ALK2 inhibitorPharmaceuticalsKeros Therapeutics, Inc.
Feb 27, 202411,912,750GDNF fusion polypeptides and methods of use thereofBiotechnologyKeros Therapeutics, Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 9, 20252025/0312415ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOFPharmaceuticalsKeros Therapeutics, Inc.
Sep 25, 20252025/0295735ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOFPharmaceuticalsKeros Therapeutics, Inc.
Sep 11, 20252025/0282877METHODS OF USING ALK2 AND ALK3 ANTIBODIESPharmaceuticalsKeros Therapeutics, Inc.
Aug 28, 20252025/0270333ALK2 ANTIBODIES AND METHODS OF USE THEREOFPharmaceuticalsKeros Therapeutics, Inc.
Aug 28, 20252025/0270287ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOFPharmaceuticalsKeros Therapeutics, Inc.
Jun 26, 20252025/0206799ACTIVIN RECEPTOR TYPE IIB VARIANTS AND METHODS OF USE THEREOFPharmaceuticalsKeros Therapeutics, Inc.
Jun 12, 20252025/0188148METHODS OF ADMINISTERING AN ACTIVIN RECEPTOR TYPE IIB VARIANTPharmaceuticalsKeros Therapeutics, Inc.
Jan 30, 20252025/0034148METHODS OF USING ALK2 INHIBITORSPharmaceuticalsKeros Therapeutics, Inc.
Aug 1, 20242024/0252631METHODS OF USING ACTIVIN RECEPTOR TYPE II SIGNALING INHIBITORSPharmaceuticalsKeros Therapeutics, Inc.
Jul 11, 20242024/0228583ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOFPharmaceuticalsKeros Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 13 · Biotechnology 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton KROS · research, not advice